Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Bychkovsky BL, Li T, Sotelo J, Tayob N, Mercado J, Gomy I, et al. Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program. Clin Cancer Res. 2022;28(11):2349-2360.

Parra-Herran C, Khani F, Wobker SE. Gender distribution of editors and authors of reference textbooks in anatomic pathology: further edits are required. Mod Pathol. 2022;35(12):1784-1790.

Taylor AS, Setia N, Alpert L, Zhao L, Lamps LW, Hart J, et al. Measuring the Submucosal Depth of Invasion in Endoscopic Mucosal Resections for Barrett-associated Adenocarcinoma: Practical Issues and Relevance for the Decision for Esophagectomy. Arch Pathol Lab Med. 2022;146(11):1338-1344.

Liao D, Geyer JT, Kacker A. Cervical Lymphadenopathy in an Elderly Man. JAMA Otolaryngol Head Neck Surg. 2022;148(7):686-687.

Pagano MB, Foroutan F, Goel R, Allen ES, Cushing MM, Garcia DA, et al. Vitamin K antagonist reversal strategies: Systematic review and network meta-analysis from the AABB. Transfusion. 2022;62(8):1652-1661.

Leung W, Teater M, Durmaz C, Meydan C, Chivu AG, Chadburn A, et al. SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis. Cancer Discov. 2022;12(7):1782-1803.

Nickeleit V, Singh HK, Davis VG, Seshan SV. Classifying Polyomavirus Nephropathy: The "Banff" Initiative. Transpl Int. 2022;35:10299.

Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022;399(10324):541-553.

Singhal S, Hellyer J, Ouseph MM, Wakelee HA, Padda SK. Autoimmune Disease in Patients With Advanced Thymic Epithelial Tumors. JTO Clin Res Rep. 2022;3(5):100323.

Lakkaraja M, Scordo M, Mauguen A, Cho C, Devlin S, Ruiz JD, et al. Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation. Blood Adv. 2022;6(3):1054-1063.